dc.contributor.authorMa, Xing
dc.contributor.authorTeh, Cathleen
dc.contributor.authorZhang, Quan
dc.contributor.authorBorah, Parijat
dc.contributor.authorChoong, Cleo Swee Neo
dc.contributor.authorKorzh, Vladimir
dc.contributor.authorZhao, Yanli
dc.date.accessioned2015-03-03T02:50:33Z
dc.date.available2015-03-03T02:50:33Z
dc.date.copyright2014en_US
dc.date.issued2014
dc.identifier.citationMa, X., Teh, C., Zhang, Q., Borah, P., Choong, C. S. N., Korzh, V., et al. (2014). Redox-responsive mesoporous silica nanoparticles : a physiologically sensitive codelivery vehicle for siRNA and doxorubicin. Antioxidants & redox signaling, 21(5), 707-722.en_US
dc.identifier.issn1523-0864en_US
dc.identifier.urihttp://hdl.handle.net/10220/25156
dc.description.abstractAims: Efficient siRNA/drug codelivery carriers can offer great promises to cancer treatment on account of synergistic effect provided from cancer-associated gene and anticancer drugs. In this work, a redox-responsive drug/siRNA codelivery vehicle based on mesoporous silica nanoparticles was fabricated to simultaneously deliver siRNA and doxorubicin (Dox) in vitro and in vivo. Results: The nanoparticle surface was functionalized with the adamantane (AD) units. Formation of stable host–guest complex between disulfide bond linked-AD and ethylenediamine-modified β-cyclodextrin is capable of fully blocking drugs inside the nanopores, while amino groups can complex with siRNA via electrostatic interaction. Relatively high concentration of glutathione in biophysical environment provides natural reducing agent to trigger drug/siRNA release by cleaving pre-introduced disulfide bonds. B-cell lymphoma 2 (Bcl-2) siRNA was codelivered to silence Bcl-2 protein expression in HeLa cells, resulting in enhanced chemotherapy efficacy in vitro. In vivo delivery experiment carried out in transgenic zebrafish larvae indicates that the delivery of Dox inhibits the development of choroid plexus in a dose-dependent manner, leading to successful decrease of green fluorescence protein transcription in choroid plexus. Reduction of liver tumor was also demonstrated after injection of Dox-loaded nanoparticles. Innovation: We successfully demonstrated that functional nanoparticles could serve as an efficient carrier for the delivery of Bcl-2 siRNA and Dox in HeLa cells and in transgenic zebrafish larvae, leading to enhanced therapeutic efficacy. Conclusion: Enhanced cytotoxicity caused by simultaneous delivery of Bcl-2 siRNA and Dox was observed in HeLa cells. Drug-loaded nanoparticles were internalized in vivo, inhibiting the development of choroid plexus and the progression of liver tumor.en_US
dc.language.isoenen_US
dc.relation.ispartofseriesAntioxidants & redox signalingen_US
dc.rights© 2014 Mary Ann Liebert. This paper was published in Antioxidants & Redox Signaling and is made available as an electronic reprint (preprint) with permission of Mary Ann Liebert. The paper can be found at the following official DOI: [http://dx.doi.org/10.1089/ars.2012.5076].  One print or electronic copy may be made for personal use only. Systematic or multiple reproduction, distribution to multiple locations via electronic or other means, duplication of any material in this paper for a fee or for commercial purposes, or modification of the content of the paper is prohibited and is subject to penalties under law.en_US
dc.subjectDRNTU::Science::Medicine
dc.titleRedox-responsive mesoporous silica nanoparticles : a physiologically sensitive codelivery vehicle for siRNA and doxorubicinen_US
dc.typeJournal Article
dc.contributor.schoolSchool of Materials Science and Engineeringen_US
dc.contributor.schoolSchool of Physical and Mathematical Sciencesen_US
dc.identifier.doihttp://dx.doi.org/10.1089/ars.2012.5076
dc.description.versionPublished versionen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record